Drug Approval | May 19, 2026
FDA expands Enhertu use in early HER2-positive breast cancer
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Access to genomic testing, not therapy cost, is the biggest challenge
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Highlighting KEYTRUDA & expanding cancer pipeline
Initiatives include scholarships, STEM initiatives, and healthcare capacity-building programmes supporting women and girls across 52 countries
Digital platform records over 1.34 crore beneficiary registrations with QR-enabled MCH cards and real-time monitoring features
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Subscribe To Our Newsletter & Stay Updated
